Treatment with IL15 or scFvB1IL15 was also able to significatively increase the levels of another NK-activating receptor, NKp30 (13.78 ± 3.99% of NKp30-positive NK cells in CLL PBMCs treated with IL15 and 20.69 ± 5.01% in CLL PBMCs treated with scFvB1IL15 versus 7.68 ± 3.39% for non-treated CLL PBMCs, p = 0.002). This evidence concerns the gene SLAMF6 and B-cell chronic lymphocytic leukemia.